Payment overview · 2025
General Payments
$2,378.45
152 reported records · 22 companies
Healthcare provider profile · identity verified
Dylan Thomas Werth, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LEES SUMMIT, MO · NPI 1306112594
Verified facts
What the public records show
CMS Open Payments records show Dylan Thomas Werth, M.D. received $2,378.45 in general payments during 2025 across 152 reported records.
ABBVIE INC. accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Jardiance, Mounjaro, Nurtec Odt, Ozempic, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Arexvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $513.99 | 21.6% | 42 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $403.58 | 17.0% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $227.59 | 9.6% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $199.57 | 8.4% | 23 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $192.20 | 8.1% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $185.41 | 7.8% | 13 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $164.95 | 6.9% | 10 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $84.85 | 3.6% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $66.31 | 2.8% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $49.20 | 2.1% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $47.56 | 2.0% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $45.54 | 1.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.98 | 1.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.55 | 1.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.32 | 1.1% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.05 | 0.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $18.10 | 0.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.57 | 0.7% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $15.68 | 0.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.51 | 0.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.98 | 0.6% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $8.96 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,378.45 | 152 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $351.96 | 31 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $350.05 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $227.59 | 12 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $216.06 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $166.10 | 21 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $164.95 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $162.53 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $147.92 | 19 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $134.87 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $118.17 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $118.17 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $113.42 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $103.68 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $97.83 | 11 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $84.85 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $66.31 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $50.21 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $49.20 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $48.61 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $47.65 | 5 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $47.56 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $46.58 | 3 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $45.54 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.96 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.98 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.32 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.18 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $8.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 27 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 83 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 58 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 84 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 11 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
84 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
84 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
83 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 378 | 113 |
| Lisinopril | Lisinopril | 378 | 104 |
| Omeprazole | Omeprazole | 193 | 59 |
| Alprazolam | Alprazolam | 188 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 188 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 187 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 184 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 156 | 47 |
| Losartan Potassium | Losartan Potassium | 155 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 154 | 47 |
| Gabapentin | Gabapentin | 153 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 48 |
| Simvastatin | Simvastatin | 137 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 136 | 42 |
| Metformin Hcl | Metformin Hcl | 134 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 40 |
| Trazodone Hcl | Trazodone Hcl | 106 | 29 |
| Meloxicam | Meloxicam | 98 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 98 | 22 |
| Metformin Hcl Er | Metformin Hcl | 97 | 29 |
| Methylprednisolone | Methylprednisolone | 90 | 72 |
| Furosemide | Furosemide | 89 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 86 | 16 |
| Allopurinol | Allopurinol | 85 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 85 | 23 |
| Jardiance | Empagliflozin | 84 | 24 |
| Eliquis | Apixaban | 83 | 20 |
| Tramadol Hcl | Tramadol Hcl | 83 | 28 |
| Carvedilol | Carvedilol | 80 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 77 | 63 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 14 |
| Ezetimibe | Ezetimibe | 66 | 21 |
| Montelukast Sodium | Montelukast Sodium | 64 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | 15 |
| Farxiga | Dapagliflozin Propanediol | 58 | 16 |
| Potassium Chloride | Potassium Chloride | 58 | 18 |
| Xarelto | Rivaroxaban | 55 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 16 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 23 |
| Glipizide | Glipizide | 44 | 11 |
| Bupropion Xl | Bupropion Hcl | 43 | 13 |
| Levofloxacin | Levofloxacin | 43 | 33 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 42 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 41 | 14 |
| Buspirone Hcl | Buspirone Hcl | 41 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 16 |
| Sertraline Hcl | Sertraline Hcl | 38 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 14 |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 29 |
| Famotidine | Famotidine | 36 | 16 |
| Finasteride | Finasteride | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | 12 |
| Chlorthalidone | Chlorthalidone | 31 | 11 |
| Prednisone | Prednisone | 31 | 17 |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 27 | 27 |
| Fluconazole | Fluconazole | 27 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 26 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 15 |
| Lorazepam | Lorazepam | 24 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | 17 |
| Pregabalin | Pregabalin | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 17 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Glyburide | Glyburide | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 15 |
| Acyclovir | Acyclovir | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Prolia | Denosumab | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,378.45 · 152 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AMYVID, APLENZIN, AREXVY, Arikayce, Auvelity, BEXSERO, BREZTRI, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FARXIGA, FREESTYLE LIBRE 3, General - Pain Management, JARDIANCE, KISUNLA, LINZESS, MOUNJARO, NEXLETOL, NEXPLANON, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error